文献速递神经肿瘤神经重症

内镜经鼻颅底术后视力恶化的原因、治疗与结局

Visual deterioration after endonasal endoscopic skull base surgery: causes, treatments, and outcomes.
PubMed 文献 · J Neurosurg · 2021-10-01

及时干预使81%患者视力恢复,永久性视力恶化率为0.33%。压迫性病因经早期再手术均可逆,缺血性病因经补氧与高血容量升压治疗约半数改善。

要点

  • 术后视力恶化罕见但需警惕,颅咽管瘤、脑膜瘤和垂体腺瘤风险较高。
  • 压迫性病因(血肿或移植物移位)应尽早再手术减压,本组均恢复至基线。
  • 缺血性病因可试用补氧与高血容量升压治疗,但约半数可能遗留永久损害。

核心结论

  • 内镜经鼻蝶术后视力恶化虽罕见,但及时恰当干预可有效治疗,压迫性病因可逆,缺血性病因约半数可改善。

研究设计与样本

  • 回顾性分析Weill Cornell/NewYork-Presbyterian Hospital 2010—2020年由资深作者实施的1200例连续内镜经鼻蝶手术病例。

主要发现

  • 视力恶化平均发生于术后28.8小时,超过70%患者在最初13小时内出现视力丧失。
  • 压迫性病因11例(血肿8例、移植物移位3例),分别发生于术后7.3小时和70.3小时,在腺瘤中更常见。
  • 缺血性病因10例,发生于术后10.3小时,在颅咽管瘤和脑膜瘤中更常见(p=0.08)。
  • 16例(76.2%)行早期再手术探查减压;11例压迫性病例再手术后视力均恢复至基线,10例缺血性病例中6例经补氧和高血容量升压治疗改善(p=0.02)。

关键数值与推荐

  • 及时干预使81%患者视力恢复,永久性视力恶化率为0.33%。
  • 急性术后视力恶化在硬性关闭中更常见(4.78%) vs 软性关闭(1.03%;p=0.0006)。
  • 缺血性病因中视力部分恢复者,术后8至16小时液体扩容(p=0.034)和32至48小时收缩压升高(p=0.05)显著高于持续视力缺损者。

临床怎么用

  • 术后早期出现视力恶化应迅速评估病因,压迫性病因尽早再手术减压。
  • 缺血性病因可尝试补氧和高血容量升压治疗,避免不必要的探查手术延误。
  • 对颅咽管瘤、脑膜瘤和垂体腺瘤等高危病理及硬性关闭病例加强术后视力监测。

局限性

  • 回顾性单中心研究,样本来自单一资深术者,结果外推需谨慎。
  • 缺血性病因与病理类型的关联仅达p=0.08,未达传统显著性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Visual deterioration after endoscopic endonasal transsphenoidal surgery (EETS) for sellar and parasellar masses is a rare but serious complication caused by either compressive or ischemic mechanisms. Timely diagnosis and intervention may restore vision if instituted appropriately. The associated risk factors and their relation to the success of intervention are not well understood. METHODS: The authors examined a series of 1200 consecutive EETS cases performed by the senior author at Weill Cornell/NewYork-Presbyterian Hospital from 2010 to 2020. Cases with postoperative visual deterioration were identified. Pre- and postoperative clinical data, mechanism of visual decline, latency to intervention, and long-term visual outcome were retrospectively collected and analyzed with appropriate statistical methods. RESULTS: Twenty-one patients (1.75%) complained of early postoperative visual deterioration. The most common pathology associated with postoperative visual loss was craniopharyngioma (7.69%), followed by meningioma (5.43%) and then pituitary adenoma (1.94%). Timely intervention restored vision in 81% of patients for a 0.33% rate of permanent visual deterioration. Average time to visual deterioration was 28.8 hours, and over 70% of patients experienced vision loss within the first 13 hours. Compressive etiology (n = 11), consisting of either hematoma (n = 8) or graft displacement (n = 3), occurred 7.3 hours and 70.3 hours after surgery, respectively, and was more common in adenomas. Acute postoperative visual deterioration was more common in firm closures (4.78%) compared with soft closures (1.03%; p = 0.0006). Ischemic etiology (n = 10) occurred 10.3 hours after surgery and was more common with craniopharyngiomas and meningiomas (p = 0.08). Sixteen patients (76.2%) underwent early reoperation to explore and decompress the optic apparatus. Vision was restored to baseline after reoperation in all 11 compressive cases, whereas 6/10 ischemic cases improved with supplemental oxygen and hypervolemic hypertensive therapy (p = 0.02). Fluid expansion from 8 to 16 hours (p = 0.034) and systolic blood pressure elevation from 32 to 48 hours (p = 0.05) after surgery were significantly higher in those ischemic patients who recovered some vision compared with those with persistent visual deficits. CONCLUSIONS: Visual deterioration after EETS is a rare event but can be effectively treated if acted upon appropriately and in a timely fashion. Compressive etiology is reversible with early reoperation. Ischemic etiology can be successfully treated in roughly half of cases with supplemental oxygen and hypertensive hypervolemic therapy but may result in permanent visual deterioration if not instituted appropriately or if delayed with unnecessary exploratory surgery.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Carnevale JA, Babu CS, Goldberg JL, et al. Visual deterioration after endonasal endoscopic skull base surgery: causes, treatments, and outcomes. J Neurosurg. 2021. PMID: 34598134. doi:10.3171/2021.3.JNS204378

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。